Birgit Parzefall

Birgit Parzefall


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Feline Medicine and Surgery Open Reports
Verified
Journal Article
Open access
NSNina Schneider
Nina Schneider
ABAndreas Blutke
Andreas Blutke
BPBirgit Parzefall
Birgit Parzefall
Case summary: A 15-week-old male British Shorthair cat was presented for peracute paralysis immediately after microchip implantation. Neurological examination revealed a non-ambulatory tetraparesis and left thoracic limb plegia localised to C1–C5 spinal cord segments. CT of the cervical spine showed a diagonally orientated metallic foreign body (microchip transponder, 10 mm in length) within the vertebral canal at the level of C1–C2, resulting in a penetrating spinal cord injury. Based on concerns about further iatrogenic spinal cord injury through surgery, medical management was chosen. Despite the severe clinical signs, the kitten returned to ambulation within 6 days of the injury, with controlled urination and defecation. Continuous neurological improvement was seen for up to 6 weeks after the injury at which point a mild-to-moderate ambulatory tetraparesis and ataxia remained, with an overall good quality of life. Follow-up CT at the age of 13 months revealed a relative cranial displacement and rotation of the microchip towards the foramen magnum, while the cat’s neurological status was unchanged. Relevance and novel information: This case demonstrated a cervical penetrating spinal cord injury in a growing cat caused by a microchip, which was successfully managed with medical treatment, suggesting that this might be an option for patients at risk of severe surgery-related complications or where owners reject surgery.

30 December 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
NSNina Schneider
Nina Schneider
ABAndreas Blutke
Andreas Blutke
KMKaspar Matiasek
Kaspar Matiasek
BPBirgit Parzefall
Birgit Parzefall
Choroid plexus tumors are commonly described as intraventricular mass lesions and account for 7–10% of intracranial, primary tumors in dogs. A 3-year-old Shetland sheepdog was presented with a history of slowly progressive lethargy, vision impairment and cognitive deficits. On magnetic resonance imaging, a subdural fluid accumulation (SFA) overlying and compressing the left parietotemporal lobe as well as multifocal changes consisting of cyst-like lesions, supposed intra-axial brain lesions and mild, multifocal meningeal thickening and generalized contrast enhancement were identified. Cerebrospinal fluid (CSF) analysis showed a mononuclear pleocytosis with negative results for infectious agents. The dog was treated with prednisolone followed by burr hole craniotomy with puncture of the SFA, which macroscopically appeared to be CSF-like fluid. After initial improvement, the dog deteriorated despite continuation of prednisolone and cytarabine therapy and was euthanized four weeks after surgery. Histopathology was consistent with a disseminated, neuroinvasive choroid plexus carcinoma (CPC) that involved the entire neuroaxis including the meninges of the brain and spinal cord. Immunohistochemical examination showed a strong Kir7.1 and a heterogenous cytokeratin-immunoreactivity in neoplastic cells. In conclusion, a CPC should be considered as a possible cause of a SFA even in the absence of an intraventricular mass lesion.

3 August 2026 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Open access
ASAnnika Katharina Schmitz
Annika Katharina Schmitz
AAAlexander Paul Sablotni Aguilera
Alexander Paul Sablotni Aguilera
GBGesine Buhmann
Gesine Buhmann
JRJana van Renen
Jana van Renen
BPBirgit Parzefall
Birgit Parzefall
AFAndrea Fischer
Andrea Fischer
Objectives: Immune-mediated polyneuropathy (IMPN) manifests with generalised lower motor neuron (LMN) weakness and a remittent or relapsing clinical course. Evidence-based treatment recommendations for severely or chronically affected cats are limited. The objective of this study was to evaluate the clinical course and outcome of cats with IMPN after treatment with human intravenous immunoglobulins (hIVIg). Methods: Medical records from two veterinary referral hospitals were reviewed (2018–2025) for cats with IMPN treated with hIVIg. Cats were treated with 1–2 g/kg hIVIg divided over 2–4 days (0.5 g/kg/day). Clinical information, diagnostic findings, treatment details, and short- and long-term follow-up were evaluated retrospectively. Follow-up information was obtained from medical records and owner communication. Minimum follow-up duration was 8 months (range 8–51; median 17). Clinical course (partial and complete recovery, relapses) was compared between cats with acute/recent onset (four cats) or chronic presentation (five cats). Results: Of nine cats, eight exhibited clinical improvement after hIVIg administration, achieving ambulatory status (walking >5 steps) within a median of 4 days (range 2–8). One cat failed to respond to hIVIg but improved after subsequent prednisolone therapy. For the overall cohort, the median time to complete recovery was 20 days, while the median time to partial recovery was 14 days. Relapses occurred in four cats, but weakness was less severe, and all cats recovered again. The remaining five cats remained relapse-free. Conclusions and relevance: Human IVIg was well tolerated in this small cohort, and rapid clinical improvement was observed in most treated cats. These findings suggest that hIVIg may be considered as a treatment option in selected cats with IMPN, including those with acute and chronic presentations. Larger prospective studies, including comparison with no treatment or corticosteroids, are warranted to further assess its efficacy.